Relmada Therapeutics (RLMD) FCF Margin (2012 - 2013)
Relmada Therapeutics (RLMD) reported FCF Margin of 493.19% for Q4 2013, down 56285.0% year-over-year from N/an in Q4 2012, and down 293.28% quarter-over-quarter from 125.4% in Q1 2013.
Relmada Therapeutics (RLMD) FCF Margin (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has 2 years of FCF Margin data on file, last reported at 493.19% in Q4 2013.
- FCF Margin for Q4 2013 came in at 493.19%, down 56285.0% year-over-year; the trailing twelve-month figure through Nov 2013 was 249.81% (changed N/A YoY), and the FY2013 annual result was 196.12%, down 10086.0% from the prior year.
- FCF Margin eased to 493.19% in Q4 2013 per RLMD's latest filing, from 125.4% in the prior quarter.
- Over five years, FCF Margin peaked at 69.66% in Q4 2012 and troughed at 496.5% in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2013 | -493.19% |
| Feb 28, 2013 | -125.40% |
| Nov 30, 2012 | 69.66% |
| Aug 31, 2012 | -220.73% |
| May 31, 2012 | -496.50% |